Topic: obesity drugs

Rhythm plays well in stellar rare obesity data

Boston’s Rhythm has produced highly impressive results for its FDA “breakthrough” candidate setmelanotide in people with an ultra-rare genetic disease that causes early onset obesity due to insatiable hunger.